April 4 (Reuters) - Boston Scientific ( BSX ) said on

Thursday the U.S. Federal Trade Commission (FTC) has requested

additional information from the medical device maker related to

its $3.7 billion deal to buy Axonics ( AXNX ).

In a regulatory filing, Boston Scientific ( BSX ) said Axonics ( AXNX ) has

also received a request for additional information from the FTC

and both the companies expect to respond promptly.

Boston said it now expects the deal, announced in January,

to be completed in the second half of 2024 following the FTC's

request, compared to its previous estimate of first half.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi

Majumdar and Shinjini Ganguli)